| Patient | Edward W. Brooke |
|---|---|
| Date of birth | 1942-10-26 |
| Identifiers | MRN HR-ML014-SYN; SSN (made up) 000-14-5063 |
| Document date | 2026-08-11 |
| Author | Howard Bellamy, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Survivorship visit on tamoxifen. [S]
Mr. Brooke returns three months after his last visit, about nine and a half months into tamoxifen and ten months after surgery. He has missed no doses. Hot flashes remain mild; libido is unchanged and he is not troubled by it. He has had no leg swelling or pain, chest pain, breathlessness, or change in vision, and no new lump, skin change, or swelling on either side of the chest or in either armpit, no bone pain, cough, or weight loss. Since his last visit he has begun speaking publicly about breast cancer in men, to encourage men to have a lump or discomfort in the chest checked and to ask their doctors to examine them. He walks most days and feels well. [S]
| Element | Detail |
|---|---|
| Tamoxifen | About nine and a half months; no missed doses |
| Side effects | Mild hot flashes; lower libido, not bothersome |
| Recurrence symptoms | None |
| Function | Independent; walking most days; busy with speaking and writing |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fatigue, fever, or weight loss |
| Endocrine | Positive | Mild hot flashes |
| Cardiovascular | Negative | No chest pain or leg swelling or pain |
| Respiratory | Negative | No cough or breathlessness |
| Musculoskeletal | Negative | No bone pain |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Tamoxifen 20 mg oral tablet, one tablet by mouth once daily (adjuvant endocrine therapy, planned for at least five years) | One tablet once daily | Oral route | 2025-10-28 | active | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 2026-02-10 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-11 | Body height | 183 | cm | S |
| 2026-08-11 | Body weight | 82 | kg | S |
| 2026-08-11 | Body mass index (BMI) [Ratio] | 24.5 | kg/m2 | S |
| 2026-08-11 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-08-11 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-08-11 | Heart rate | 68 | /min | S |
| 2026-08-11 | Respiratory rate | 14 | /min | S |
| 2026-08-11 | Body temperature | 36.7 | Cel | S |
| 2026-08-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-11 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
Vital signs recorded on 2026-08-11; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Chest wall | Mastectomy scars healed on both sides; no nodule or skin change |
| Lymph nodes | No axillary, supraclavicular, or cervical nodes |
| Abdomen | Soft; liver not enlarged |
| Musculoskeletal | No spinal tenderness |
| Extremities | Arm circumferences equal; no calf swelling or tenderness |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Invasive ductal carcinoma of the right male breast, central (retroareolar) portion, stage IIA (pT1c pN1a M0), grade 2, ER positive, PR positive, HER2 negative; treated by bilateral mastectomy and right axillary lymph node dissection; on adjuvant tamoxifen; synthetic modern detail linked to his publicly disclosed breast cancer | active | confirmed | C50.121 | S — Synthetic tumor size, grade, receptor status, and stage; the diagnosis, the right side, the operation, and the spread to lymph nodes are from his public account (D). |
| Estrogen receptor-positive status of the breast cancer | active | confirmed | Z17.0 | S — Synthetic receptor result; his tumor biology was not made public. |
| Long-term use of tamoxifen, with safety monitoring (venous thromboembolism, mood, hot flashes, sexual side effects, adherence) and bone health review | active | confirmed | Z79.810 | S — Synthetic adjuvant therapy in the modern episode. |
| Absence of both breasts after bilateral mastectomy | active | confirmed | Z90.13 | S — The double mastectomy is reported publicly (D); the coding is synthetic. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Cancer-related history and examination of both sides of the chest wall and both axillae | Every 3 to 6 months for 3 years | Completed today | No evidence of recurrence |
| Examination | Lymphedema assessment | Every visit after axillary surgery | Completed today | No arm swelling |
| Medication safety | Venous thromboembolism symptoms on tamoxifen | Every visit on tamoxifen | Completed today | None |
| Medication safety | Hot flashes on tamoxifen | Every visit on tamoxifen | Completed today | Mild |
| Medication safety | Sexual side effects of tamoxifen | Every visit on tamoxifen | Completed today | Lower libido, stable; no treatment wanted |
| Medication safety | Adherence to tamoxifen | Every visit on tamoxifen | Completed today | No missed doses |
| Survey | Distress and depression screen (PHQ-2) | Every visit | Completed today | PHQ-2 score 0 |
| Survey | Fatigue and cognitive concerns | Every visit | Completed today | None |
| Imaging | Bone density (DXA) | Every 2 years on hormone therapy | Up to date | Six months ago; next in eighteen months |
| Imaging | Breast imaging (mammography) | Yearly only for a remaining breast after lumpectomy, or the other breast with a predisposing variant | Not indicated | Both breasts were removed; there is no breast tissue to image |
| Laboratory | Routine blood tests, tumor markers, and CT, bone scan, or PET | Not recommended without symptoms in stage I to III disease | Not indicated | No symptoms suggesting recurrence |
| Self-management | Survivorship care plan and lifestyle counseling | Within a year of treatment; lifestyle every visit | Completed today | Written plan given; at least 150 minutes of activity a week; no tobacco or alcohol |
Goal progress:
Guideline basis: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); Runowicz CD, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); Shapiro CL, et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline (2019); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026)
Follow-up: Annual wellness visit in two months. Survivorship visit in three to six months. Medical oncology every six months. Next scheduled visit 2026-10-13: subsequent annual wellness visit. [S]